Skip to main content

Advertisement

Table 3 Treatment on demand in patients with HAE-nlC1-INH

From: Abstracts of 11th C1-inhibitor Deficiency & Angioedema Workshop

  Total (32/143 = 22.3%) HAE-F12 (24/116 = 19.8%) HAE-Unknown (8/25 = 28%)
n % n % n %
Icatibant 7 21.9 3 12.5 4 50.0
C1-inhibitor 3 9.4 1 4.2 2 25.0
Tranexamic acid 25 78.1 21 87.5 4 50.0
Danazol 1 3.1 0   1 12.5